RxDoctor Payments Data

Shujauddin Khan, MD

General Practice · Sandston, VANPI 1114126067

Payments from drug & device makers

$3,533in general payments, 2019–2025

Across 198 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$649
  • Lilly USA, LLC$636
  • AstraZeneca$496
  • GSK$370
  • Pfizer$253
  • Amarin Pharma, Inc.$216
  • plus $912 from 18 others

What the payments were for

  • Food & beverage$3,533100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,533 in reported general payments places this provider in the 90th percentile of 2,591 general practice providers in Virginia.

See all general practice providers in Virginia

Medicare billing

Part B allowed, 2024
$203,572
Medicare patients
283
Services billed
2,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$87,723
MounjaroTirzepatide72$84,026
TrulicityDulaglutide35$45,803
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$42,373
EliquisApixaban28$32,006
TivicayDolutegravir Sodium12$31,371
PifeltroDoravirine12$24,520
FarxigaDapagliflozin Propanediol18$17,852
XareltoRivaroxaban20$16,507
Bydureon BciseExenatide Microspheres14$11,384
LinzessLinaclotide18$11,124
Janumet XrSitagliptin Phos/Metformin Hcl16$8,302
WelcholColesevelam Hcl12$7,538
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,024
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$6,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$636$131,705125 claims
Novo NordiskOzempic$649$87,72362 claims
GSKTrelegy Ellipta$370$42,37326 claims
MerckPifeltro, Janumet Xr$63$32,82228 claims
PfizerEliquis$253$32,00628 claims
AstraZenecaFarxiga, Breztri Aerosphere$496$24,87529 claims
AbbVieLinzess$76$11,12418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,591 general practice providers in Virginia.

Other general practice in Sandston

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →